Plasmodium vivax is an important cause of malaria, associated with a significant public
health burden. Whilst enhanced malaria-control activities have successfully reduced the …

Achieving a malaria-free world presents exciting scientific challenges as well as
overwhelming health, equity, and economic benefits. WHO and countries are setting …

Background Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been
associated with relapse prevention through the clearance of P. vivax parasitemia and …

Abstract Background Treatment of Plasmodium vivax malaria requires the clearing of
asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared …

Background Primaquine is the only widely used drug that prevents Plasmodium vivax
malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to …

Protozoan Plasmodium parasites are the causative agents of malaria, a deadly disease that
continues to afflict hundreds of millions of people every year. Infections with malaria …

Background Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria
despite increasing reports of treatment failure. We did a systematic review and meta …

Background Primaquine radical cure is used to treat dormant liver-stage parasites and
prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We …

Background Primaquine is the only licensed drug for eradicating Plasmodium vivax
hypnozoites and, therefore, preventing relapses of vivax malaria. It is a vital component of …

The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …